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Immune cells have an important effect of the prognosis of human colorectal cancer 
(CRC). Infiltration of CRC tissue by cytotoxic CD8 T cells, T helper 1 (Th1) cells, 
CXCR5+ follicular T helper cells (Tfh) and Foxp3+ T regulatory cells (Tregs) is 
associated with improved patient survival and a favorable clinical outcome (Nat Rev 
Cancer 2012;12;298-306). In this study, Cremonesi et al aimed to identify the nature 
of chemotactic factors promoting CRC infiltration by these T cell populations and the 
stimuli responsible for inducing their expression in the CRC microenvironment.  
 
The investigators analyzed gene expression of a variety of T cell markers in 62 CRC 
and corresponding tumor free colonic tissues, to study the composition of T cell 
populations within these tissues. They found that CRC tissues were only minimally 
infiltrated by Th2 cells, as indicated by undetectable levels of IL4 and minimal 
expression of IL5 and IL13. However, Th17 and Treg cell markers were highly 
expressed in CRC cells in comparison to control tissues, whilst CD4 T-helper cell 
and TfH cell markers were slightly reduced. Unsupervised hierarchical analysis of 
the data resulted in CRC samples being clustered into 3 main groups based on 
expression of T cell markers - cluster high (overexpression of most T cell markers), 
cluster het  (heterogeneous expression of T cell markers) and cluster low 
(downregulation of all T cell markers). In the cluster high group, a specific panel of 
chemokine genes was found to be significantly upregulated. Furthermore, specific 
highly significant correlations were noted between T cell markers and chemokine 
genes in CRC samples, indicating particular chemokines could drive T cell 
recruitment into CRC tissues.  
 
The investigators also studied chemokine receptor profiles of T cells in CRC samples 
in comparison with control tissues or peripheral blood mononuclear cells (PBMCs).  
In the group with overexpression of T cell markers, chemokine genes were found to 
be significantly upregulated, indicating certain chemokines could drive T cell 
recruitment into CRC tissues.  Specifically, they found that CCR5, CXCR3 and 
CXCR4 were highly expressed on CD8, CD4 and FoxP3 T cells in both cancer and 
control tissues. However, significantly higher proportion of CCR5+ and CXCR4+ T 
cells were detected in cancer tissues in comparison with PBMCs.  
 
Further interrogation of the data, enabled the investigators to identify particular 
chemokine signatures for each CRC T cell subset i.e. mainly CCR5-binding ligands 
(CCL3, CCL4, CCL5, CCL8), CXCR3-binding ligands (CXCL9 and CXCL10) and a 
CXCR4-binding ligand (CXCL12) for cytotoxic T lymphocytes; CCR4 ligands 
(CCL17, CCL22), CCR5-binding ligands (CCL3, CCL5), CXRC3-binding ligands 
(CXCL9, CXCL10) and CXCL12 for Th1 cells; CCR4 ligands (CCL17, CCL22), 
CXCL12, CCL5 and CXCL9 for Treg cells; CXCL13 for Tfh cells; and CCL20 and 
CCL17 for Th17 cells. The authors concluded from these data that the 
overexpression of the chemokines they identified associates with the infiltration of 
beneficial T cell populations and improved prognosis. 
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Gene expression analysis of chemokines in CRC samples identified that tumor cells 
were the main source of T-cell recruiting chemokines including CCL3, CCL4, CCL5 
and CXCL10 (which bind to receptors on cytotoxic T cells and Th1 cells) but not 
CCL7, CCL8, CCL11, CCL13, CCL27 and the Th17 recruiting chemokines CCL17 
and CCL22. Crucially, authors also noticed that in vitro cultured CRC cell lines 
expressed far fewer chemokine genes in comparison to primary tumor cells, 
suggesting that chemokine expression may require other environmental factors 
present in the in vivo setting.  
 
The authors hypothesized that this environmental signal may potentially arise from 
the gut microbiota, given that it has been previously demonstrated that commensal 
bacteria and/or their products can translocate across CRC epithelial tissues and thus 
come into direct contact with CRC cells (Science 2012; 338:120-3). The authors 
exposed CRC cells from cell lines and CRC organoids to TLR agonists. This resulted 
in upregulation of constitutively expressed chemokine genes including CCL20, 
CXCL9 and CXCL10 and de novo expression of additional chemokine genes, 
including CCL3, CCL4, CCL5 and CCL22. Several chemokine genes were also 
induced on exposure of CRC cells to particular bacterial species known to be 
enriched in CRC tissues; Fusobacterium nucleatum, Bacteroides fragilis and 
Escherichia coli.  
 
To determine whether such effects were also present in the in vivo setting, 
chemokine expression was measured in CRC tumor xenografts generated by 
injecting human CRC cells into NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). 
These mice, also called NOD scid gamma mice, are a type of immunodeficient 
mouse that lack mature T cells, B cells and natural killer (NK) cells. The injection of 
tumor cells was performed either intra-peritoneally or intra-cecally. Interestingly, they 
noticed that intracecal tumors contained significantly higher levels of a range of 
chemokines compared to intraperitoneal controls - CCL5 (70-fold increase), CCL20 
(19-fold increase), CXCL10 (12-fold increase) and CXCL11 (3-fold increase). 
Furthermore, levels of these chemokines significantly reduced following treatment 
with antibiotics and correlated with bacterial load. By adoptively transferring CSFE 
(carboxyfluorescein diacetate succinimidyl ester)-labelled tumor infiltrating CD4+ and 
CD8+ T lymphocytes, into these tumor-xenograft bearing mice, the authors observed 
that these tumor-infiltrative lymphocytes homed to intracaecal xenografts to a much 
greater extent than intraperitoneal xenografts. Hence, taken together, these 
experiments suggest that the commensal gut microbiota is a major factor in inducing 
chemokine expression in CRC cells which subsequently determines T cell infiltration 
into tumor tissues.  
 
To characterize microbiota-chemokine-T cell relationship in clinical CRC samples, 
the investigators sought to identify significant biological correlations. Although higher 
quantities of gut bacteria were observed in highly T cell infiltrated CRC samples in 
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comparison to poorly infiltrated tumors, total bacterial load (as assessed by 16S 
analysis) only weakly correlated with individual chemokine expression in contrast to 
the observations in tumor xenografts. Instead, analysis of individual bacteria genera 
in highly infiltrated and poorly infiltrated CRC tumor samples, revealed significant 
correlations between specific bacteria and T cell markers and chemokine gene 
expression. Lachnospiraceae and Ruminococcaceae, both part of the Firmicutes 
phylum, correlated strongly with CCR5 and CXCR3 binding chemokines. 
Bacteroides and Proteobacteria, in particular Methylobacteriaceae, also significantly 
correlated with the expression of all prognostically favorable T cell markers and 
corresponding chemokines. The authors concluded that the expression of 
chemokines by human CRC cells is associated with the abundance of specific 
bacteria within the tumors. 
 
Comment 
 
The importance of immune cells in cancer pathogenesis has become increasingly 
appreciated. CRC, in particular, has become a paradigmatic tumor for understanding 
the complex role of immune cells in cancer. 
  
It is now recognized that the developing CRC resides within a rich microenvironment 
comprised of a complex array of immune cell populations including T lymphocytes, B 
lymphocytes, macrophages, dendritic cells, NK cells, and mast cells, which are found 
either within the tumor core (TC), the invasive margin (IM) or in tertiary lymphoid 
structures. This is collectively referred to as the “immune contexture” (Nat Rev 
Cancer 2012;12:298–306). 
  
The clinical significance of these immune cells in human CRC was first noted in the 
2000s, when it was demonstrated that the type, density and location of immune cells 
within tumor samples are a better predictor of prognosis than the established 
histopathological Dukes’ staging system (Science 2006;313:1960–1964). A strong 
immune cell reaction in both the TC and IM, comprising of CD8 cytotoxic T cells and 
CD45RO memory T cells, correlated with favorable prognosis regardless of cancer 
stage, whilst a poor immune reaction in both regions correlated with poor prognosis 
even in those with minimally invasive (Stage 1) tumors (Science 2006;313:1960–
1964, J Clin Oncol 2009;27:5944–5951). This led to the development of a novel, 
immune scoring system for CRC, based on memory and cytotoxic T cell markers, 
which was found to be superior to the Dukes’ staging in predicting recurrence as well 
as survival (J Clin Oncol 2009;27:5944–5951, J Clin Oncol 2011;29:610–618). More 
recent studies have revealed that other components of the immune contexture 
including T regulatory cells, B cells, NK cells, macrophages, as well as endothelial 
cells and fibroblasts, also correlate with CRC prognosis. 
  
In parallel to these developments, a major transcriptomic analysis identified that the 
vast majority of CRCs fall into four distinct consensus molecular subtypes: CMS1 
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(tumors exhibiting high microsatellite instability (MSI) due to mutations in genes 
encoding DNA mismatch-repair proteins), CMS2 (tumors with high chromosomal 
instability (CIN) and activation of the Wnt and MYC pathways), CMS3 (tumors with 
KRAS mutations and disruption of metabolic pathways) and CMS4 (tumors with a 
mesenchymal phenotype and frequent CpG island methylator phenotype (CIMP)) 
(Nat Med 2015;21:1350-6). This has prognostic implications, as CMS4 is associated 
with the worst disease-free survival and overall survival, and both CMS1 and CMS4 
with poor survival after recurrence (Ann Onc 2018; 29(Suppl 8):viii18).   
  
Using a transcriptome-based computational method, these molecular and immune 
based classifications of CRC were recently integrated (Clin Cancer Res 
2016;22:4057-4066). It was found that unlike CMS2 and CMS3 CRC subtypes, 
CMS1 and CMS4 subtypes displayed a strong immune and inflammatory contexture. 
CMS1 contained higher abundances of cytotoxic T cells, whilst CMS4 had higher 
expression of B cells, myeloid cells, fibroblasts and endothelial cells. In addition, 
CMS1 subtype cancers expressed high levels of T cell attracting chemokines 
(including CXCL9, CXCL10, CXCL16), Th1 cytokines (IFNg and IL15), immune 
checkpoints (e.g. CTLA4, PD1) and MHC class 1. CMS4 subtype, however, 
expressed high levels of myeloid chemokines (e.g. CCL2), complement components, 
angiogenic factors (VEGFB, VEGFC, and PDGFC), and immunosuppressive 
molecules (TGFB1, TGFB3, LGALS1, and CXCL12). CMS2 and CMS3 subtypes 
were relatively devoid of immune cell populations. 
  
These findings demonstrate that CRC is a heterogeneous disease, comprising of 
distinct molecular and immune signatures, requiring different therapeutic strategies. 
For instance, CMS1 subtype cancers are most likely to respond to checkpoint 
inhibitor therapy such as pembrolizumab (an anti-PD1 antibody), whilst CMS4 
subtype cancers may require a combination of anti-angiogenic, anti-TGF-beta and 
checkpoint inhibitor therapies (Curr Opin Immunol 2016;39:7-13).  
  
In this study, Cremonesi et al, aimed to further characterize the chemokine signals 
that drive favorable T cell populations into the CRC microenvironment and identify 
the cellular sources of these chemokines, and the potential underlying stimuli 
responsible for inducing their expression. They found chemokine genes expressed 
by CRC cells in response to gut microbiota-derived stimuli are mainly responsible for 
the infiltration of favorable immune cell populations into the CRC microenvironment. 
This is an exciting discovery, as it could potentially lead to the addition of an entirely 
new strategy in our armamentarium against CRC – one which involves modulation of 
the CRC immune contexture by targeting the gut microbiota. 
  
In the past decade, evidence of the involvement of bacterial populations during 
tumor progression was identified using metagenomic tools (Nat Genet 2002; 30: 
141-142, PLoS ONE 2011;6: e 19838.doi:10.1371). This approach demonstrated 
that a number of bacteria are involved in the pathogenesis of CRC including 
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Fusobacterium nucleatum, Bacteroides fragilis and Escherichia coli. F. nucleatum is 
an anaerobe which is highly invasive (Infect Immun 2000; 68:3140-3146, Gut 2011; 
60:34-40), with pro-inflammatory characteristics (Infect Immun 2000;68:2907-2915, 
Cytokine 2009; 46:201-210)  and known to be present in CRC specimens. F. 
nucleatum has been proposed to promote the pathogenesis of CRC by a variety of 
mechanisms including creating a pro-inflammatory environment with increased levels 
of TNF and NF-κB, the activation of β-catenin signaling and reducing T cell activation 
(World J Gastrointest Oncol 2018;10:71-81). B. fragilis has been found to be an 
independent predictor of three year survival from CRC (Oncotarget 2016;7:46158-
72). It secretes a toxin which is a metalloprotease that cleaves E-cadherin, thereby 
activating the Wnt pathway (JCI 2014;124:4166-72). E. coli have been found to 
frequently colonize CRC and have been reported to have mutagenic effects (World J 
Gastroenterology 2014;20:6560-6572, Cell, Host and Microbe 2014;15:317-28). 
Some gut bacteria metabolize bile salts into procarcinogenic secondary bile acids 
whereas bacteria fermentation of complex carbohydrates into short fatty acids is 
anticarcinogenic (Nat Rev Microbiol 2014;12:661). Biofilms, which are polybacterial 
communities encased in a polymeric matrix, are found in only 15% of healthy 
patients but in 100% of right-sided colorectal cancers. The colonic mucosa under 
biofilms have decreased E-cadherin, and increased IL-6, Ki-67 and phospho-stat3, 
suggesting biofilms play a procarcinogenic role (PNAS 2014;111:18321). 
 
In the current study, a range of bacteria including in particular Lachnospiraceae and 
Ruminococcaceae were associated with the expression of T cell recruiting 
chemokines. Fusobacteria which have previously been associated with poor 
prognosis were found to evoke T cell recruiting chemokines in this study, suggesting 
that they may in some circumstances be associated with a good prognosis. Clearly 
more detailed studies of individual bacteria grouping are required to define the 
specific circumstances in which they encourage recruitment of favorable T cell 
populations. The potential effect of gut bacteria on the other cell populations 
comprising the CRC immune contexture also need to be investigated.   
 
In conclusion, the intestinal microbiota is being found to play an increasingly 
important role in determining the prognosis of a range of cancers including CRC. The 
gut microbiota is already known to be a key determinant of checkpoint inhibitor 
therapy (Gastroenterology 2018;154:2068-70). These new observations that a range 
of gut bacteria can promote T cell infiltration into CRC which could confer a good 
prognosis, opens another exciting avenue for future treatments. 
 
